Relay Therapeutics (RLAY) Enterprise Value (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Enterprise Value data on file, last reported at -$642.1 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 586.39% year-over-year to -$642.1 million in Q1 2026; TTM through Mar 2026 was -$642.1 million, a 586.39% decrease from a year earlier, with the FY2025 full-year figure at -$554.5 million, down 346.16% from the prior year.
• Enterprise Value for Q1 2026 stood at -$642.1 million, down from -$554.5 million in the prior quarter.
• Over the last five years, Enterprise Value for RLAY reached as high as -$91.6 million in Q3 2025 and fell as low as -$642.1 million in Q1 2026.
• Historically, Enterprise Value has averaged -$199.7 million across 5 years, with a median of -$145.9 million in 2023.
• Across the five-year window, Enterprise Value surged 58.57% in 2022 and sank 586.39% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$151.8 million in 2022, then increased by 5.31% to -$143.7 million in 2023, then grew by 13.53% to -$124.3 million in 2024, then slumped by 346.16% to -$554.5 million in 2025, then retreated by 15.79% to -$642.1 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$642.1 million in Q1 2026, -$554.5 million in Q4 2025, and -$91.6 million in Q3 2025.